Pathogenesis and approaches to therapy of membranoproliferative glomerulonephritis
In 1965, it was observed that patients with glomerulonephritis with persistently low serum concentrations of C3 evolved to have similar glomerular morphologic characteristics, particularly recognizable in biopsy specimens stained by the Jones methenamine silver technique [1] . Subsequent observations have indicated that although long-standing hypocomplementemia is commonly observed and is unique in patients with these glomerular morphologic characteristics, reduced C3 concentrations are not always present [2, 3] and the distinctive morphology is now the criterion for identification of the disease. Thus, the name first given, hypocomplementemic persistent (chronic) glomerulonephritis [1] , is no longer appropriate and the descriptive terms membranoproliferative and mesangiocapillary glomerulonephritis have subsequently been applied.
With time, electron microscopy of the glomerular lesion has shown that, based on the location of the glomerular deposits, patients with membranoproliferative morphologic characteristics fall into two groups. In about two-thirds of the patients [4] , the deposits are present in the mesangium and in the subendothelial space. The basement membrane is normal. This form has been designated type I membranoproliferative glomerulonephritis (MPGN). In the remainder of the patients, deposits are present within the glomerular basement membrane as well as within the mesangium; subendothelial deposits are scanty or absent. This form, designated type II MPGN, or intramembranous dense deposit disease, was first recognized independently in 1963 [5] . In this form, dense deposits are also found in the basement membranes of Bowman's capsule and of the tubules. In addition, lobular glomerulonephritis is now recognized as a form of MPGN [4, 6, 7] . It should be noted that I type I MPGN may occasionally be seen in the nephritis accompanying chronic bacteremia, systemic lupus erythematosus and anaphylactoid purpura [4, 8] .
The two types of MPGN have similar clinical manifestations but in clinical course they differ in that, as a group, crescents are more often present in type II and survival is shorter [4, 9] . They also differ immunologically. In type I, the serum complement profile is often indicative of classical pathway activation and immunohistologic study always indicates glomerular deposits of C3 and properdin and, in many cases, significant amounts of immunoglobulin, Clq and C4 [4, 9, 10, 11] . In type lIthe complement profile is suggestive of alternative pathway activation and a complement-reactive factor, the C3 nephritic factor, is more often demonstrable in the serum than in patients with type I disease [9, 10, 11] . By immunofluorescence, C3 is abundant in the glomeruli but immunoglobulins, early reacting components of complement and properdin are either absent or present in only small amounts [4, 9, 10, 11] .
In this paper, details of the glomerular morphology in MPGN are reviewed as a setting for a review of current concepts of etiology and pathogenesis. In the light of these observations, possible approaches to therapy are discussed.
Glomerular morphology
All forms of the disease have in common marked hyperplasia of the mesangium. A characteristic of type I disease is the presence of mesangial interposition, consisting of extensions of mesangial cells, or of whole mesangial cells, into the subendothelial space. This together with the mesangial hyperplasia greatly compromises capillary lumens and is responsible for the interpretation of early workers that the basement membrane, as viewed in PAS-and silverstained preparations, was split ("double contoured" or "tram-track" appearance). By electron micros-copy, however, the true basement membrane appears largely intact.
In type 11 disease, the mesangial hyperplasia may be less severe, capillary lumens less compromised and the glomeruli less frequently enlarged [4, 10, 12] . Mesangial interposition and the double contoured appearance may be present only in a patchy distribution [4, 10, 12] and the capillary walls are thickened by the hallmark of the disease, the deposition of electron dense material within the glomerular basement membrane. Hump-like subepithelial deposits are often present and may be numerous [9] .
In the lobular form of the disease, the markedly accentuated lobulation of the glomerulus is due to profound mesangial hyperplasia, increase in mesangial matrix and to the presence of centrolobular sclerotic nodules, the hallmark of this variant. Capillary lumens, confined to the periphery of the enlarged lobules, are greatly reduced in diameter [6] . The deposits may be those characteristic of either type I or type II disease [10] .
The correlation between glomerular morphologic characteristics and function is poor [4, 13] . The gbmerular filtration rate may be normal even when open capillary lumens are infrequent and capillary walls are greatly thickened by mesangial interposition or dense deposits.
A characteristic of the disease which has a bearing on therapeutic trials is the infrequency with which spontaneous improvement in glomerular morphology is observed. Although proliferation and lobularity may tend to diminish in severity with time [10, 14] , it is unusual to observe significant changes in morphologic characteristics [4] even though the disease may go into a complete remission with respect to clinical manifestations. Occasionally, mesangial interposition and the dense intramenbranous deposits may regress [10] . One patient in each of two series of cases showed spontaneous improvement in glomerular morphologic characteristics [15, 16] and in one of these the improvement was not striking [15] .
Etiology
The cause of the disease is not known. The onset is often without symptoms and not observed by the physician. In some patients, the diagnosis follows the chance discovery of proteinuria and microhematuria [14] and in others, old medical records have revealed that proteinuria and hematuria antedated symptoms by a long period (nine years in one case) [1, 15] . A "silent" onset is said to be more common in type I disease [9] .
The fact that a number of patients at presentation have an acute nephritic syndrome and marked gbmerular proliferation and exudation [1, 14, 17] raises the question of whether the disease represents a Sequella of acute poststreptococcal glomerulonephritis. The apparent onset occasionally follows a streptococcal infection. This sequence is observed more often in type II than in type I disease [9, 10] . In type II disease, numerous subepithelial deposits resembling "humps" may be present [9, 17] . In those with a symptomless onset, one might postulate a subclinical acute poststreptococcal glomerubonephritis as the initiating event. There is, however, no firm evidence for this origin.
The disease has been seen in siblings [16, 18] and a predisposition to it may be inherited or, conceivably, it might be the result of an infectious agent. In one of thesereports, both siblings had type I MPGN [16] .
Of great interest is the observation that type II MPGN occurs with high frequency in patients with partial lipodystrophy [19] [20] [21] . Such patients are frequently hypocomplementemic and a complement-reactive factor, presumably the C3 nephritic factor, is demonstrable in their serum [19, 22] . Further study of the lipodystrophic patients has shown that they fall into three groups, those with neither hypocomplementemia and nephritis, those with hypocomplementemia only and those with both hypocomplementemia and nephritis [23] . It would appear that hypocomplementemia develops first, followed by the nephritis.
Based in part on these observations, Peters and Williams [23] have postulated that a deficiency of a complement component may result in immune complex disease by predisposing the patient to recurrent or chronic infection. Since ability to form antibody is unimpaired, circulating immune complexes become abundant. An unusual number of patients with complement deficiency have developed some form of gbomerubonephritis. Gbomerulonephritis has been observed in patients with Clr deficiency [24] , with hereditary angioedema (low concentrations of C2 and C4) [19, 24] and with C2 deficiency [24, 25] . On the other hand, complement deficiency appears to predispose to recurrent or chronic infection only in patients with deficiency centering about C3 and CS but none of these have had nephritis [26] [27] [28] . C2 deficiency, for example, may be associated with no abnormality [29] , or symptoms of systemic lupus erythematosus may be present but the syndrome is noteworthy for the absence of glomerulonephritis [23] . Only two patients with C2 deficiency have had recurrenl [30] or chronic [31] infection but neither had evidence of renal disease.
With one exception [22] , patients with partial lip-odystrophy have not been noted to be subject to recurrent or chronic infection [21, 32] . To explain the association of MPGN with partial lipodystrophy, it would be equally attractive to postulate that the event initiating the lipodystrophy is a viral infection and that persistent shedding of virus, perhaps in combination with an abnormal immune response, as postulated by Peters and Lachmann [33] , leads to genesis of nephritic factor and of nephritogenic complexes which uniquely produce type II MPGN.
Pathogenesis
Role of glomerular deposits in pathogenesis. In type I MPGN, the glomerular deposition of material capable of activating the classical complement pathway appears to be responsible for the glomerular inflammatory reaction. Immunofluorescence studies have usually shown, in addition to C3, the presence of Clq, C4, properdin and immunoglobulins in the glomerular deposits [4, 9, 10] . It has been suggested that the occasional patient with type I disease without deposits containing immunoglobulins, properdin and early reacting components has a different disease [9, 10] . However, it seems equally possible that the determinants of immunoglobulin and early reacting components may become undetectable because of extensive deposition of C3 or because the material composing the deposits is intermittently present in the circulation and, in its absence, degradation of determinants of previously deposited material occurs. In serial biopsies, lgG has been detectable in some specimens but not in others [8] . Evidence that the material comprising the deposits activates the classical pathway while in the circulation is provided by the complement profile as will be described in the following.
The glomerular morphology in type I MPGN would suggest that the material deposited in the glomeruli cannot penetrate the glomerular basement membrane. Since the studies of Farquhar and Palade [34] , it has been known that particles which cannot penetrate the glomerular basement membrane accumulate in the mesangium. They showed that such particles accumulate first in the subendothelial space and then, apparently by movement in the subendothelial space, reach the axial portion of the capillary where they enter the mesangium. In chronic serum sickness produced in rabbits by daily injections of bovine serum albumin (BSA), it was noted [16] that animals which produce intermediate amounts of antibody to BSA form relatively large circulating complexes which deposit exclusively in the mesangium. In these animals, however, the complete morphologic picture of MPGN was not produced. The only experimental disease resembling MPGN is the nephritis which accompanies trypanosomiasis in monkeys [35] .
Assuming glomerular morphology is dependent on complex penetrability, disease resembling type I MPGN would be expected to occur in other human nephritides if impenetrable nephritogenic complexes were present. The development of this glomerular morphology in occasional cases of lupus and anaphylactoid nephritis and of the nephritis of chronic bacteremia [4, 8] is thus understandable. In type II MPGN, the nature of the complexes and their role in pathogenesis is not clear. In this form, the deposits present in the mesangium and in the basement membranes fluoresce only with labeled antibody to C3 [9, 10] . Immunoglobulins are usually absent or present in scanty amounts in the mesangium and early reacting complement components and properdin are not detectable. The fact that dense deposits containing C3 are found not only in the glomerular basement membrane but also in the basement membranes of Bowman's capsule and of the tubules [4, 5, 7, 9, 10] makes it difficult to explain the disease as the result of deposition of complexes which can partially penetrate the glomerular basement membrane. Also difficult to explain is the poor survival rate of patients with type II disease. The deposits in the glomerular basement membrane appear to be relatively benign; they persist even though other aspects of glomerular morphology and the clinical status of the patient improve with therapy [12] and may be abundant in transplanted kidneys which show otherwise little morphologic or clinical evidence of glomerulonephritis [36] . Deposits, other than in the basement membrane, are often less abundant than in type I and, presumably as a consequence, mesangial proliferation is often less severe [4, 10, 12] . Thus, it is difficult to understand the greater predisposition of patients with type II disease to develop crescents and to have rapid deterioration of function [9] .
The pathogenesis of the lobular form of the disease is also not clear; conceivably this form represents an altered host response.
Role of complement in pat hogenesis. Although early studies of complement in MPGN gave evidence that the hypocomplementemia was produced by alternative pathway activation and thus differed from other hypocomplementemic nephritides, recent observations have required revision of this concept. Early studies focused on the role of the C3 nephritic factor as causative of the hypocomplementemia. Activity of this factor in producing C3 conversion was demonstrable in the absence of early reacting complement components [37] and was found to be dependent on the presence of factor B and other components of the alternative pathway [38, 39] . It is now known, however, that complement concentrations in the two forms of MPGN differ. In type I disease, the hypocomplementemia, as assessed by C3 concentrations, is often not marked and varies considerably with time [10] . In type II disease, markedly depressed C3 concentrations are frequently observed and the levels often remain low over long periods [9, 10] .
Measurements of other complement components have given evidence that in type I disease, classical pathway activation is occurring. Clq [11] and C4 [10, 11] concentrations may be reduced whereas low levels of these components are less frequently observed in type II disease [9] [10] [11] and C3NeF activity is more often demonstrable in the serum [11] . In both types, CS concentrations may be low in parallel with the reduction in C3 [11] .
Whereas the nephritic factor appears primarily responsible for the low C3 concentrations in type II disease, a large contribution to the maintenance of the low levels in some patients is apparently a reduced synthesis of C3 [40] [41] [42] . Reduced C3 synthesis has also been observed in lupus nephritis [43] and reduced C4 synthesis can be seen in patients with hereditary angioedema [44] . It seems possible that the reduced synthesis seen in these conditions is the result of a negative feedback imposed on the synthetic mechanism by the presence in the plasma of breakdown products of the complement proteins. The origin of the C3 nephritic factor is unknown. Presumably, its activity is not dependent on the presence of the kidneys in that nephritic factor activity persists for at least two weeks after bilateral nephrectomy [45] . Others have observed that total complement and C3 concentrations may remain markedly depressed for up to several years after bilateral nephrectomy [10, 14, 15] .
Whereas the role of complement in the pathogenesis of type I disease could be said to be similar or identical to its role in lupus and acute poststreptococcal glomerulonephritis, its role in type II disease is obscure. There is no evidence of a direct relationship of the C3 nephritic factor, or of alternative pathway activation, to the course of the glomerulonephritis [2, 3, 46] . Highly active nephritic factor may be present over long periods in patients whose nephritis is quiescent or, as in patients with partial lipodystrophy, nonexistant [22] , and, conversely, deterioration in renal function in type II disease may occur over periods in which nephritic factor is not demonstrable in the serum.
Approaches to therapy
The foregoing considerations suggest that, particularly in type I disease, if complex deposition in the glomeruli could be halted, resolution of the glomerular lesion might occur. There is currently no readily available method to demonstrate the presence of nephritogenic complexes in the circulation. Until such methods are available, the success of therapy designed to reduce glomerular deposits would appear to be best judged from serial renal biopsies. As pointed out by others [13] , the clinical characteristics of MPGN make in many patients the renal biopsy the best means of judging the success of therapy. However, should therapy improve glomerular morphologic aspects, it is currently not possible to determine whether the success was due to inhibition of complex formation or inhibition of complex deposition. and Cochrane [48] [49] [50] has indicated that subendothelial deposition of colloidal carbon as well as of immune complexes in glomerular capillaries is fostered by histamine. In immune complex nephritis in rabbits, the histamine is liberated from platelets as a result of an immune reaction which leads to the production of a platelet-releasing factor by basophils [51] . The disease can be ameliorated or prevented by use of antihistamines or by platelet depletion [50, 52] . Studies by Bolton, Spargo and Lewis [53] have given evidence that an antihistamine can also delay the onset of autologous immune complex nephritis in rats.
That these observations are not applicable to disease in man would be predicted from the fact that whole blood histamine concentrations are far less than in the rabbit [54] and there is virtually no histamine in platelets [55] . Histamine in human blood is virtually all in basophils and, under certain conditions, in eosinophils [55, 56] . To date there is no evidence for the participation of these cells in human glomerulonephritis. In MPGN it would be intriguing to speculate that the anaphylatoxins derived from the involvement of C3 or C5 in the alternate pathway reaction produced by the nephritic factor release sufficient histamine to produce complex deposition. The points against the role for this mechanism are, first, that an anaphylatoxin inactivator is abundant in plasma and prevents significant histamine release [57] and, secondly, that the clinical course of MPGN does not correlate with either C3 or C3NeF concentrations [2, 3, 46] . Although it is impossible to make predictions from existing data, there is at present little evidence that the antagonists of vasoactive amines would be effective in the therapy of MPGN.
Therapy by prevention of complex formation. The aim of immunosuppressive therapy, using courses of cytotoxic agents often combined with corticosteroid, has been, of course, to reduce the formation of immune complexes. Many workers have attempted this form of therapy but the regimens used did not appear to alter the course of the disease [4] . The data, however, do not provide firm evidence that this approach, or a modification of it, would be of no value. In most instances, serial renal biopsies permitting assessment of changes in glomerular morphology were not performed. Moreover, the courses of therapy may not in all cases have been of sufficient duration to allow demonstration of an effect. It seems possible that even if complex formation had been slowed or stopped by the therapy, demonstrable improvement in glomerular morphology would occur only after periods measured in years. Studies by Wegmann and Leumann [58] emphasize this point. In two patients with nephritis due to an infected ventriculoatrial shunt, specimens from repeat renal biopsies performed 7 to 22 months after the shunt had been removed and immune complexes presumably eradicated from the circulation showed the continued presence of subendothelial deposits, mesangial hyperplasia and mesangial interposition.
According to preliminary data, two therapeutic regimens may be effective in MPGN. Specimens of serial renal biopsies from patients who for long periods had received a regimen consisting of either cyclophosphamide, anticoagulants and dipyridamole [59, 60] or high-dose alternate-day prednisone [12] have shown a reduction in the population of glomerular deposits and partial restitution of glomerular architecture. Wider use and, ideally, prospective controlled trials of these regimens will be necessary to define their merits. Results of a controlled trial of an alternate-day regimen employing prednisone at a lower dose than used in the original study [12] , being conducted by the International Study of Kidney Disease in Children, are not yet available. In the case of the triple-therapy regimen [59, 60] , efforts should be made to identify the effective constituent or constituents. The constituents of both regimens might be predicted to prevent complex formation but an effect in halting complex deposition cannot be ruled out. 
